FMAD_ASPFU
ID FMAD_ASPFU Reviewed; 400 AA.
AC A0A067Z9B6; Q4WAY5; Q4WAY6;
DT 07-SEP-2016, integrated into UniProtKB/Swiss-Prot.
DT 01-OCT-2014, sequence version 1.
DT 03-AUG-2022, entry version 41.
DE RecName: Full=O-methyltransferase af390-400 {ECO:0000303|PubMed:24568283};
DE EC=2.1.1.- {ECO:0000269|PubMed:24568283};
DE AltName: Full=Fumagillin biosynthesis methyltransferase {ECO:0000303|PubMed:24568283};
DE Short=Fma-MT {ECO:0000303|PubMed:24568283};
GN Name=af390-400 {ECO:0000303|PubMed:24568283};
GN Synonyms=fmaD {ECO:0000303|PubMed:24082142}; ORFNames=AFUA_8G00390/400;
OS Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC
OS A1100) (Aspergillus fumigatus).
OC Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiomycetidae; Eurotiales; Aspergillaceae; Aspergillus;
OC Aspergillus subgen. Fumigati.
OX NCBI_TaxID=330879;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC STRAIN=ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100;
RX PubMed=24568283; DOI=10.1021/ja500881e;
RA Lin H.C., Tsunematsu Y., Dhingra S., Xu W., Fukutomi M., Chooi Y.H.,
RA Cane D.E., Calvo A.M., Watanabe K., Tang Y.;
RT "Generation of complexity in fungal terpene biosynthesis: discovery of a
RT multifunctional cytochrome P450 in the fumagillin pathway.";
RL J. Am. Chem. Soc. 136:4426-4436(2014).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100;
RX PubMed=16372009; DOI=10.1038/nature04332;
RA Nierman W.C., Pain A., Anderson M.J., Wortman J.R., Kim H.S., Arroyo J.,
RA Berriman M., Abe K., Archer D.B., Bermejo C., Bennett J.W., Bowyer P.,
RA Chen D., Collins M., Coulsen R., Davies R., Dyer P.S., Farman M.L.,
RA Fedorova N., Fedorova N.D., Feldblyum T.V., Fischer R., Fosker N.,
RA Fraser A., Garcia J.L., Garcia M.J., Goble A., Goldman G.H., Gomi K.,
RA Griffith-Jones S., Gwilliam R., Haas B.J., Haas H., Harris D.E.,
RA Horiuchi H., Huang J., Humphray S., Jimenez J., Keller N., Khouri H.,
RA Kitamoto K., Kobayashi T., Konzack S., Kulkarni R., Kumagai T., Lafton A.,
RA Latge J.-P., Li W., Lord A., Lu C., Majoros W.H., May G.S., Miller B.L.,
RA Mohamoud Y., Molina M., Monod M., Mouyna I., Mulligan S., Murphy L.D.,
RA O'Neil S., Paulsen I., Penalva M.A., Pertea M., Price C., Pritchard B.L.,
RA Quail M.A., Rabbinowitsch E., Rawlins N., Rajandream M.A., Reichard U.,
RA Renauld H., Robson G.D., Rodriguez de Cordoba S., Rodriguez-Pena J.M.,
RA Ronning C.M., Rutter S., Salzberg S.L., Sanchez M., Sanchez-Ferrero J.C.,
RA Saunders D., Seeger K., Squares R., Squares S., Takeuchi M., Tekaia F.,
RA Turner G., Vazquez de Aldana C.R., Weidman J., White O., Woodward J.R.,
RA Yu J.-H., Fraser C.M., Galagan J.E., Asai K., Machida M., Hall N.,
RA Barrell B.G., Denning D.W.;
RT "Genomic sequence of the pathogenic and allergenic filamentous fungus
RT Aspergillus fumigatus.";
RL Nature 438:1151-1156(2005).
RN [3]
RP BIOTECHNOLOGY.
RX PubMed=14913169; DOI=10.1126/science.115.2977.71;
RA Killough J.H., Magill G.B., Smith R.C.;
RT "The treatment of amebiasis with fumagillin.";
RL Science 115:71-72(1952).
RN [4]
RP BIOTECHNOLOGY.
RX PubMed=9177176; DOI=10.1073/pnas.94.12.6099;
RA Sin N., Meng L., Wang M.Q., Wen J.J., Bornmann W.G., Crews C.M.;
RT "The anti-angiogenic agent fumagillin covalently binds and inhibits the
RT methionine aminopeptidase, MetAP-2.";
RL Proc. Natl. Acad. Sci. U.S.A. 94:6099-6103(1997).
RN [5]
RP BIOTECHNOLOGY.
RX PubMed=12075057; DOI=10.1056/nejmoa012924;
RG Agence Nationale de Recherches sur le SIDA 090 Study Group;
RA Molina J.M., Tourneur M., Sarfati C., Chevret S., de Gouvello A.,
RA Gobert J.G., Balkan S., Derouin F.;
RT "Fumagillin treatment of intestinal microsporidiosis.";
RL N. Engl. J. Med. 346:1963-1969(2002).
RN [6]
RP BIOTECHNOLOGY.
RX PubMed=18209961; DOI=10.1007/s00011-007-7075-5;
RA Lazarus D.D., Doyle E.G., Bernier S.G., Rogers A.B., Labenski M.T.,
RA Wakefield J.D., Karp R.M., Clark E.J., Lorusso J., Hoyt J.G.,
RA Thompson C.D., Hannig G., Westlin W.F.;
RT "An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates
RT the pathophysiological disease processes of rheumatoid arthritis.";
RL Inflamm. Res. 57:18-27(2008).
RN [7]
RP FUNCTION.
RX PubMed=23488861; DOI=10.1021/ja312503y;
RA Lin H.C., Chooi Y.H., Dhingra S., Xu W., Calvo A.M., Tang Y.;
RT "The fumagillin biosynthetic gene cluster in Aspergillus fumigatus encodes
RT a cryptic terpene cyclase involved in the formation of beta-trans-
RT bergamotene.";
RL J. Am. Chem. Soc. 135:4616-4619(2013).
RN [8]
RP INDUCTION.
RX PubMed=24116213; DOI=10.1371/journal.pone.0077147;
RA Dhingra S., Lind A.L., Lin H.C., Tang Y., Rokas A., Calvo A.M.;
RT "The fumagillin gene cluster, an example of hundreds of genes under veA
RT control in Aspergillus fumigatus.";
RL PLoS ONE 8:E77147-E77147(2013).
RN [9]
RP IDENTIFICATION, INDUCTION, AND DISRUPTION PHENOTYPE.
RX PubMed=24082142; DOI=10.1073/pnas.1313258110;
RA Wiemann P., Guo C.J., Palmer J.M., Sekonyela R., Wang C.C., Keller N.P.;
RT "Prototype of an intertwined secondary-metabolite supercluster.";
RL Proc. Natl. Acad. Sci. U.S.A. 110:17065-17070(2013).
CC -!- FUNCTION: O-methyltransferase; part of the gene cluster that mediates
CC the biosynthesis of fumagillin, a meroterpenoid that has numerous
CC biological activities including irreversible inhibition of human type 2
CC methionine aminopeptidase (METAP2) (PubMed:23488861, PubMed:24568283).
CC The pathway begins with the conversion of farnesyl pyrophosphate (FPP)
CC to beta-trans-bergamotene by the membrane-bound beta-trans-bergamotene
CC synthase af520 (PubMed:23488861). The initial oxidation of beta-trans-
CC bergamotene by the multifunctional cytochrome P450 monooxygenase af510
CC involves C-H hydroxylation at the bridgehead C5 position to yield 5R-
CC hydroxyl-beta-trans-bergamotene (PubMed:24568283). Subsequently, a four
CC electron oxidation initiated at C-9 coupled to cleavage of the
CC cyclobutane C5-C8 bond of the bicyclo[3.1.1] core yields the
CC epoxyketone intermediate 5-keto-cordycol (PubMed:24568283). An
CC additional epoxidation reaction also catalyzed by af510 then furnishes
CC the characteristic bisepoxide ketone 5-keto-demethoxyfumagillol
CC (PubMed:24568283). 5-keto-demethoxyfumagillol is then subjected to
CC successive C-6 hydroxylation and O-methylation by the dioxygenase af480
CC and O-methyltransferase af390-400, respectively, to yield 5-keto-
CC fumagillol, which is then stereoselectively reduced by the keto-
CC reductase af490 to 5R-hydroxy-seco-sesquiterpene (PubMed:24568283). The
CC next step is the polyketide transferase af380-catalyzed transfer of a
CC dodecapentaenoyl group synthesized by the polyketide synthase af370
CC onto 5R-hydroxy-seco-sesquiterpene which leads to the production of
CC prefumagillin (PubMed:24568283). Finally, oxidative cleavage by the
CC monooxygenase af470 converts prefumagillin to fumagillin
CC (PubMed:24568283). {ECO:0000269|PubMed:23488861,
CC ECO:0000269|PubMed:24568283}.
CC -!- PATHWAY: Secondary metabolite biosynthesis; terpenoid biosynthesis.
CC {ECO:0000269|PubMed:24568283}.
CC -!- INDUCTION: Expression is controlled by the fumagillin biosynthesis
CC cluster regulator fumR (PubMed:24082142). Expression is also under the
CC control of the developmental and secondary metabolism regulator veA
CC (PubMed:24116213). {ECO:0000269|PubMed:24082142,
CC ECO:0000269|PubMed:24116213}.
CC -!- DISRUPTION PHENOTYPE: Completely abolishes the production of fumagillin
CC (PubMed:24082142). {ECO:0000269|PubMed:24082142}.
CC -!- BIOTECHNOLOGY: Fumagillin and its derivatives have been intensely
CC studied for their potential use in the treatment of amebiasis,
CC microsporidiosis and rheumatoid arthritis (PubMed:14913169,
CC PubMed:12075057, PubMed:18209961). They have also interesting
CC antiangiogenic properties by the irreversible inhibition of human type
CC 2 methionine aminopeptidase (METAP2) (PubMed:9177176).
CC {ECO:0000269|PubMed:12075057, ECO:0000269|PubMed:14913169,
CC ECO:0000269|PubMed:18209961, ECO:0000269|PubMed:9177176}.
CC -!- SIMILARITY: Belongs to the class I-like SAM-binding methyltransferase
CC superfamily. Cation-independent O-methyltransferase family. COMT
CC subfamily. {ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=EAL85126.1; Type=Erroneous gene model prediction; Note=The predicted genes AFUA_8G00390 and AFUA_8G00400 have been merged into 1 gene: AFUA_8G00390/400.; Evidence={ECO:0000305};
CC Sequence=EAL85127.1; Type=Erroneous gene model prediction; Note=The predicted genes AFUA_8G00390 and AFUA_8G00400 have been merged into 1 gene: AFUA_8G00390/400.; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; KJ187001; AHL19974.1; -; mRNA.
DR EMBL; AAHF01000014; EAL85127.1; ALT_SEQ; Genomic_DNA.
DR EMBL; AAHF01000014; EAL85126.1; ALT_SEQ; Genomic_DNA.
DR RefSeq; XP_747164.1; XM_742071.1.
DR RefSeq; XP_747165.1; XM_742072.1.
DR AlphaFoldDB; A0A067Z9B6; -.
DR SMR; A0A067Z9B6; -.
DR STRING; 746128.CADAFUBP00008396; -.
DR GeneID; 3504500; -.
DR GeneID; 3504501; -.
DR KEGG; afm:AFUA_8G00390; -.
DR KEGG; afm:AFUA_8G00400; -.
DR eggNOG; KOG3178; Eukaryota.
DR OrthoDB; 817726at2759; -.
DR UniPathway; UPA00213; -.
DR Proteomes; UP000002530; Chromosome 8.
DR GO; GO:0008171; F:O-methyltransferase activity; IEA:InterPro.
DR GO; GO:0032259; P:methylation; IEA:UniProtKB-KW.
DR GO; GO:0016114; P:terpenoid biosynthetic process; IEA:UniProtKB-UniPathway.
DR Gene3D; 1.10.10.10; -; 1.
DR Gene3D; 3.40.50.150; -; 1.
DR InterPro; IPR016461; COMT-like.
DR InterPro; IPR001077; O_MeTrfase_dom.
DR InterPro; IPR029063; SAM-dependent_MTases_sf.
DR InterPro; IPR036388; WH-like_DNA-bd_sf.
DR InterPro; IPR036390; WH_DNA-bd_sf.
DR Pfam; PF00891; Methyltransf_2; 1.
DR SUPFAM; SSF46785; SSF46785; 1.
DR SUPFAM; SSF53335; SSF53335; 1.
DR PROSITE; PS51683; SAM_OMT_II; 1.
PE 1: Evidence at protein level;
KW Methyltransferase; Reference proteome; S-adenosyl-L-methionine;
KW Transferase.
FT CHAIN 1..400
FT /note="O-methyltransferase af390-400"
FT /id="PRO_0000437041"
FT REGION 185..205
FT /note="Substrate binding"
FT /evidence="ECO:0000250"
FT ACT_SITE 309
FT /note="Proton acceptor"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01020"
FT BINDING 145..158
FT /ligand="substrate"
FT /evidence="ECO:0000250"
FT BINDING 239..240
FT /ligand="S-adenosyl-L-methionine"
FT /ligand_id="ChEBI:CHEBI:59789"
FT /evidence="ECO:0000250|UniProtKB:O04385"
FT BINDING 265
FT /ligand="S-adenosyl-L-methionine"
FT /ligand_id="ChEBI:CHEBI:59789"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01020"
FT BINDING 286..287
FT /ligand="S-adenosyl-L-methionine"
FT /ligand_id="ChEBI:CHEBI:59789"
FT /evidence="ECO:0000250|UniProtKB:O04385"
SQ SEQUENCE 400 AA; 44502 MW; 9D48606969CC6D63 CRC64;
MADIAEQLIE KLQTLETSIF EGQDATRQKL ALAARKLFHT LETKEEKTMR LAIEEPVMFS
VLQALIDTGL FEGWAAAGGG ERDVTELAKL SKRDVEPELL RHQLRLMAAN HIILETANDR
YAPTPYALAI GDKSTKVAPA LRIRTDHVAP CAMHWPDFLA KTNYRKPRDD KASCYIDTFP
EKKSFFERCS ANPVHQESFS SFMDVWAKGK RPWPEFYDTQ ALLDGADLSN GSPFVVDVGG
HHGIDLMRVA EKHPDLPAGS LVLEDLPDVV GAVHLTTDKI RTVAHDLFEE GVEQPIKGAR
AYFMHAVLHD WSDETSVKIL RQIAAVMKPG YSKVLINDIV IPSTGASCYQ AAMDCLVLQA
SANERTEAVW SKVIKDAGLK LVKYYPDGRG YESVIEAELP
